New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
08:10 EDTACST, NEPTAcasti Pharma presents preliminary data on NKPL66
Acasti Pharma (ACST), a Neptune Technologies & Bioressources (NEPT) subsidiary, announces encouraging preliminary clinical data of its "Randomized, Open-Label, Dose-Ranging, Multi-Center Trial to assess the Safety and efficacy of NKPL66 in the treatment of mild-to-high hypertriglyceridemia". In the course of planning the strategy of its phase III clinical development with CaPre, Acasti examined triglycerides data from its Open-label clinical trial.Data from 157 patients who have completed four weeks of treatment with 0.5, 1, 2 or 4 grams of CaPre per day were assessed and CaPre achieved a clinically important and statistically significant triglyceride reduction of up to 23% as compared to standard of care, after only a 4-week treatment. Moreover, a noteworthy trend indicating a dose-response relationship versus standard of care as well as clinically and statistically significant effects of doubling the doses of CaPre were observed. To date, the results of this preliminary analysis suggest that CaPre is safe and effective for the treatment of patients with triglyceride levels ranging from 200 to 500 mg/dL.
News For ACST;NEPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
08:08 EDTACSTAcasti Pharma announces positive top-line pharmacokinetic results
Subscribe for More Information
September 29, 2014
08:10 EDTACSTAcasti Pharma reports CaPre Phase II trial met primary endpoint
Acasti Pharma announces successful top-line results for its Phase II double blind, placebo controlled trial, or TRIFECTA, assessing the safety and efficacy of CaPre for the treatment of patients with hypertriglyceridemia. CaPre, Acasti's investigational new drug candidate, is composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain cardiometabolic disorders. CaPre successfully met the trial's primary endpoint achieving a statistically significant mean placebo-adjusted decrease in triglycerides from baseline to week-12, with reductions of 36.4% for 1 gram and 38.6% for 2 grams.
September 23, 2014
08:22 EDTNEPTNeptune reaches annualized production capacity of 100 metric tons at Sherbrooke
Neptune Technologies announces that its Sherbrooke plant is now operating at an annualized production capacity of 100 metric tons and customer shipments of Neptune manufactured krill oil products have commenced.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use